Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Henlius Biotech (2696 HK)
Watchlist
103
Analysis
Health Care
•
China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Watchlist
Filings
Presentations
Events
Refresh
Exchange Announcement •
16 Jul 2024 17:24
Disclosure Of Dealings Under Rule 22 Of The Takeovers Code
Attachment 1
Attachment 2
Attachment 3
Attachment 4
Exchange Announcement •
15 Jul 2024 19:27
Joint Announcement - Delay In Despatch Of Composite Document Relating To Proposed Pre-Conditional Privatisation Of Henlius By Fosun New Medicine By Way Of Merger By Absorption Of Henlius
Attachment
Exchange Announcement •
11 Jul 2024 18:26
Joint Announcement (1) Proposed Pre-Conditional Privatisation Of Henlius By Fosun New Medicine By Way Of Merger By Absorption Of Henlius And (2) Proposed Withdrawal Of Listing Fulfilment Of Pre-Condition To The Potential Share Alternative Offer
Attachment
Exchange Announcement •
02 Jul 2024 16:33
Voluntary Announcement - Hansizhuang (Serplulimab Injection) In Combination With Bevacizumab Injection And Chemotherapy Has Been Permitted To Commence An International Multicentre Phase 3 Clinical Trial For The First-Line Treatment Of Metastatic Colorectal Cancer In Japan
Attachment
Exchange Announcement •
01 Jul 2024 18:01
Appointment Of Chief Financial Officer
Attachment
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.7
x